Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATOC in SSTR Positive Patients
NCT06045260Phase 2Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177-edotreotide in Neuroendocrine Neoplasm (NEN), Paraganglioma (PGL), pheochromocytoma, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Sep 2023; status: recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)Paraganglioma (PGL)pheochromocytoma
Beyond the preview
Go deeper on NCT06045260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045260.